𝔖 Bobbio Scriptorium
✦   LIBER   ✦

NE Chemcat to widen operations with catalysts developed inhouse


Publisher
Elsevier Science
Year
2006
Weight
44 KB
Volume
2006
Category
Article
ISSN
1351-4180

No coin nor oath required. For personal study only.

✦ Synopsis


4Q 2004), while revenue for 2005 was $2.7 bn (24% over $2.2 bn in 2004). R&D expenses were $138.186 M for 4Q 2005 ($107.428 M in 4Q 2004). For 2005, R&D expenses were $502.657 M ($391.802 M in 2004). Genzyme confirmed the revenue and earnings guidance for 2006 that it provided in Jan 2006.